Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
European Urology|May 16, 2022
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the BladderBernadett Szabados, Mark Kockx, Zoe June Assaf, et al.
European Urology|February 28, 2024
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus ChemotherapyJonathan E Rosenberg, Ronac Mamtani, Guru P Sonpavde, et al.
The Prostate|December 24, 2022
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamideMaría P Fernandez-Perez, Enrique Perez-Navarro, Teresa Alonso-Gordoa, et al.
Clinical Genitourinary Cancer|January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial CarcinomaRafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.
The Journal of Urology|January 24, 2020
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective StudyNatalie J Miller, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
Cancer|December 13, 2019
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
Clinical Genitourinary Cancer|July 6, 2023
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" ExperienceDimitra Rafailia Bakaloudi, Rafee Talukder, Genevieve Ihsiu Lin, et al.
Cancers|July 27, 2024
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate CancerEnrique Perez-Navarro, Vincenza Conteduca, Juan M Funes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2021
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update ConsortiumJörg Beyer, Laurence Collette, Nicolas Sauvé, et al.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
Pageof 9